Cerus (CERS) Stock Price, News & Analysis

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CERS shares.
View CERS analyst ratings or view top-rated stocks.

3 analysts have issued 12 month price targets for Cerus' stock. Their CERS share price targets range from $2.50 to $5.00. On average, they predict the company's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 108.3% from the stock's current price.
View analysts price targets for CERS or view top-rated stocks among Wall Street analysts.

Cerus' stock was trading at $2.16 at the beginning of 2024. Since then, CERS shares have decreased by 22.2% and is now trading at $1.68.
View the best growth stocks for 2024 here.

Cerus saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 5,880,000 shares, an increase of 16.0% from the March 15th total of 5,070,000 shares. Based on an average daily trading volume, of 1,620,000 shares, the days-to-cover ratio is currently 3.6 days.
View Cerus' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CERS earnings forecast.

Cerus will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Cerus Co. (NASDAQ:CERS) announced its quarterly earnings data on Tuesday, March, 5th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.01). The biotechnology company had revenue of $46.77 million for the quarter, compared to analysts' expectations of $46.80 million. Cerus had a negative net margin of 23.98% and a negative trailing twelve-month return on equity of 67.17%.

ETFs with the largest weight of Cerus (NASDAQ:CERS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG).ARK Innovation ETF (ARKK).

Cerus updated its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $172.0 million-$175.0 million, compared to the consensus revenue estimate of $185.9 million.

15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among the company's employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA).

Cerus' stock is owned by many different institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (4.28%), Wasatch Advisors LP (3.47%) and Bouvel Investment Partners LLC (0.15%). Insiders that own company stock include Ann Lucena, Carol Moore, Chrystal Jensen, Chrystal Menard, Daniel N Swisher Jr, Eric Bjerkholt, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Vivek K Jayaraman and William Mariner Greenman.
View institutional ownership trends.

Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.